Advertisement

Topics

Pfizer to exit from Chinese generic drug JV with Hisun

00:51 EST 13 Nov 2017 | Pharmaceutical Business Review

Pfizer will exit from Hisun-Pfizer Pharmaceuticals, its Chinese joint venture (JV) for generic drugs, by divesting 49% stake to Sapphire I (HK) Holdings for an undisclosed price.

Original Article: Pfizer to exit from Chinese generic drug JV with Hisun

NEXT ARTICLE

More From BioPortfolio on "Pfizer to exit from Chinese generic drug JV with Hisun"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...